BIOVECTRA

BIOVECTRA is a part of Agilent, a leader in clinical and analytical lab technologies and specialized CDMO services. With operations in Atlantic Canada, BIOVECTRA specializes in clinical-to-commercial scale production capabilities for biologics, synthetic small molecules, highly potent APIs, and bioreagents. Its expertise has expanded into pDNA and mRNA vaccine manufacturing. Currently, it employs close to 700 people across a variety of roles in science, quality, manufacturing and production, and business administration.

Content by BIOVECTRA

BIOVECTRA is Honored with 2025 CDMO Leadership Award for Biologics

By BIOVECTRA | | 2 min read

Page 1 of 1 - 1 Total Items

September 2026

Multiplex Microscopy Becomes Easier with Encoded Antibodies

A new system that enables researchers to uniquely tag monoclonal antibodies for use in microscopy could help simplify complex imaging studies.

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Rethinking ALS Biomarkers: From Discovery to Clinical Impact

Explore how emerging biomarker research and ultrasensitive multiplex proteomics are revealing molecular signatures associated with neurodegeneration, inflammation, and disease progression in amyotrophic lateral sclerosis (ALS).

Best Practices for qPCR Assay Design and Optimization

Explore practical strategies for designing, optimizing, and validating qPCR assays to improve specificity, reproducibility, and confidence across routine and high-throughput gene expression studies.

Beyond the Basics: Strategies for Single-Cell and Spatial Transcriptomics Analysis

Explore strategies for navigating critical analytical decisions in single-cell RNA sequencing and spatial transcriptomics, from quality control and data integration to clustering, marker selection, and cell-type annotation.

Scientist reviewing cellular and molecular data on a computer in a laboratory.

Building Translation-Ready Biomarkers with Connected Workflows

Identify sources of variability and approaches for improving consistency across biomarker development.